

**Amendments to the Specification**

Additions are indicated by **underlining** and deletions are indicated by **~~striketrough~~**. Double brackets [[ ]] are used to flank text in which only underlining was removed. It is to be understood that the double brackets only indicate where the underlining has been removed relative to the original specification; **the text within the double brackets is to remain in the specification.**

A. Please replace the paragraph at page 1 lines 11-14 with the following amended paragraph:

This application is a Continuation of co-pending U.S. Application Serial No. 09/704,469 filed November 1, 2000.~~The present application~~ which claims priority to and benefit of US provisional application number 60/163,370, filed November 3, 1999, and US provisional application number 60/176,002, filed January 12, 2000, the specifications of which are incorporated herein by reference in their entirety.

B. Please replace the paragraphs at page 97, lines 12-33, and substitute therefor the following amended paragraphs:

For example, the amino acid sequence corresponding to a mouse monoclonal antibody specific for tumor necrosis factor (TNF) alpha (SEQ ID NO:1, labeled below as "1"), is aligned with a set of related human antibody sequences, e.g., amino acid sequences inferred from human antibody encoding nucleic acid sequences of the same class and/or family (SEQ ID NO:2, labeled below as "2",~~1-~~ Dersimonian et al. (1987) [[J. Immunol.]] 139: 2496-2501; SEQ ID NO:3, labeled below as "3",~~2-~~ Griffiths et al. (1993) [[EMBO J.]] 12:725-734; SEQ ID NO:4, labeled below as "4",~~3-~~ Huang et al. (1992) [[J. Clin. Invest.]] 89:1331-1343; SEQ ID NO:5, labeled below as "5",~~4-~~ Kasaian et al. (1994) [[J. Immunol.]] 152:3137-3151; and SEQ ID NO:6, labeled below as "6",~~5-~~ Welschof et al., (1995) J. Immunol. Methods 179:203-214) as follows:

-----

1

\*1 EVKLEESGGG LVQPGGSMKL SCVASGFIFS NHWNMWRQS PEKGLEWVAE  
±2 Q.Q.VQ..AE VKK..A.V.V ..K...YT.T SYA.H....A .GQR...MGW  
±3 Q.Q.VQ..AE VKK..A.V.V ..K...YT.T GYY.H....A .GQ....MGW  
±4 Q.Q.VQ..SE .KK..A.V.V .RK...YT.T GYY.N....A .GQ....MGW  
45 Q...VQ..AE VKK..V.V.V ..K...STVT .YAIH....A .GQR...MGW  
56 Q.Q.Q...AE VRK..A.V.V ..K...YILT TYY.H....A .GQ....MGL

51

\*1 IRSKSINSAT HYAESVKGRF TISRDDSKSA VYLQMIDLRI EDTGVYYCSR  
±2 .NP..NSGN. K.SQKFQ..V ..T..T.A.T A.MELSS..S ...A....A.  
±3 .NP..NSGG. N..QKFQ..V ..T..T.A.T A.MELSS..S ...A....A.  
±4 .NT..NTGNP T..QGFT... VF.L.T.V.T A...ISS.KA ...A....A.  
45 .NA..G.GN. K.SQKFQ..V ..T..T.ANT A.MELSS..S ...A....A.  
56 .NP..SGGSG GNIHKFQ..L .MT..T.T.T ..ME.SS..S ...A..F.A.